louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06390579: Automated Central Retinal Artery Occlusion Diagnosis on Fundus Photographs
Official title: Early Detection of Central Retinal Artery Occlusion Within 4.5 Hours of Visual Loss: Deep Learning Method Applied on Fundus Photographs
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: CRAO - Central Retinal Artery Occlusion
Lead sponsor: Fondation Ophtalmologique Adolphe de Rothschild
Sponsor class: NETWORK
First posted: 2024-04-30
Enrollment: 693
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Color fundus photographs taken within 30 days from the date of onset

Brief summary: Acute central retinal artery occlusion is associated with a poor prognosis and optimal treatment is not defined as randomized control trials struggle to enroll patients in part due to delayed diagnostic. Patient lack of knowledge and difficult access to ophthalmologists in emergency situations delay the diagnostic. A simple, rapid and widely accessible method that can recognize acute central retinal artery occlusion in color fundus photographs could benefit patients and doctors.The prurpose of this study is to develop, train and test a deep learning system.


Eligibility criteria: Inclusion Criteria:

* Color fundus photographs taken within 30 days from the date of onset
* diagnosis confirmed by the provider's expertise in identifying clinical symptoms and signs.

Exclusion Criteria:

* photographs with unconfirmed diagnosis
* duplicates
* photographs with combined retinal conditions
* photographs taken after thrombolysis.

Primary outcomes:
measure: Area under the receiver operating characteristic curve
timeFrame: baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Paris
country: France
facility: Hopital Fondation Adolphe de Rothschild
Study officials:
References:
Clinical trial NCT02286479: Comparison of Loop and Primary Incision&Drainage Techniques in the Emergency Department
Official title: Comparison of Loop Drainage and Primary Incision and Drainage Techniques in Patients With Cutaneous Abscess in the Emergency Department
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Skin Abscess
Lead sponsor: Kocaeli University
Sponsor class: OTHER
First posted: 2014-11-07
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Skin abscesses are among the most common soft tissue infections cause emergency room visits frequently. Management of abscess drainage and prevent further complications are important entities for emergency physicians. Historically primary incision and drainage (I\&D) technique has found very effective method of abscess drainage, however a novel technique loop drainage holds promising. The purpose of our study is comparison efficacy of I\&D and loop drainage techniques in patients with cutaneous abscess.


Eligibility criteria: Inclusion Criteria:

* Adult patients presenting to Kocaeli University Emergency Department with cutaneous abscess.
* Providing written informed consent.

Exclusion Criteria:

* Under 18 years of age.
* Immunosuppressive patients.
* Using medications have effects on wound healing.
* Abscess is not recognizable by bedside ultrasound.
* Lidocaine allergy

Primary outcomes:
measure: Abscess Resolution
timeFrame: 7 days
Secondary outcomes:
measure: Procedure Time
timeFrame: intraoperative
Other outcomes:
measure: Procedure Pain Intensity
timeFrame: intraoperative
Locations:
city: Kocaeli
country: Turkey
facility: Kocaeli University Medical Faculty Emergency Medicine Department
Study officials:
References:
citation: Ozturan IU, Dogan NO, Karakayali O, Ozbek AE, Yilmaz S, Pekdemir M, Suner S. Comparison of loop and primary incision & drainage techniques in adult patients with cutaneous abscess: A preliminary, randomized clinical trial. Am J Emerg Med. 2017 Jun;35(6):830-834. doi: 10.1016/j.ajem.2017.01.036. Epub 2017 Jan 22.
Clinical trial NCT00653679: Exercise and Muscle Protein Signalling
Official title: The Impact of Resistance Versus Endurance Exercise on the Muscle Protein Signalling Response
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Muscle Protein Synthesis
Keywords: exercise
muscle protein signalling
protein synthesis
Lead sponsor: Maastricht University Medical Center
Sponsor class: OTHER
First posted: 2008-04-07
Enrollment: 0
Sex: MALE
Minimum age (years): 18
Maximum age (years): 28
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: This study examines the muscle protein signalling response after resistance and endurance exercise. We hypothesize that the signalling response after endurance and resistance exercise will be partly similar.


Eligibility criteria: Inclusion Criteria:

* healthy men
* inactive

Exclusion Criteria:

* enrolled in a endurance and/or resistance training program

Primary outcomes:
measure: The difference in phosphorylation of different signalling proteins in the cascade towards protein synthesis
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Maastricht
country: Netherlands
facility: Maastricht University
state: Limburg
Study officials:
affiliation: Maastricht University
name: L.J.C van Loon, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03839979: HCV Viral Hepatitis, Blood Sugar Level and Systolic Blood Pressure in Egypt
Official title: Association Between HCV Viral Hepatitis, Blood Sugar Level and Systolic Blood Pressure in the Egyptian Population
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hepatitis C, Acute
Diabetes
Hypertension
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2019-02-15
Enrollment: 71975
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Egyptian patients aged 18-80 years.

Brief summary: An observational double-blind cohort study that examined the association between HCV viral hepatitis, blood sugar level and systolic blood pressure in the Egyptian population

Detailed description: a cohort study on greater than 70000 Egyptian patients had been conducted. for all patients,1- we detected the Hepatitis C Virus (HCV) RNA antigens ( hepatitis C virus)presence using BIOLINE HCV kits( qualitative test for diagnosis of hepatitis C virus in the blood), For all positive patients, confirmatory rapid screening test was performed and all patients who tested positive twice underwent a qPCR test using QIAampMinElute Virus Spin kit (Thermo Fisher Scientific, Waltham, MA, USA) performed according to the manufacturer's recommended protocol.

2- Investigators measured blood sugar levels for each patient using ACCU-CHEK kits(finger stick sugar level measurement) 3- Measured systolic blood pressure for each patient was measured using mercury meters.

4-for all patients investigators obtained full medical history regarding the presence or absence of chronic diabetes, chronic hypertension, coronary artery disease, kidney impairment with dialysis or chronic obstructive pulmonary disease.

5- for all patients investigators listed age, gender, and body mass index. 66121 patients were negative for HCV and 4852 were positive for HCV. Investigators measured the association between HCV presence, high blood sugar levels and high systolic blood pressure.

It is supposed that this is the largest study in the world that examined both associations.

In a word, this study was responding to a specific question: is hepatitis c virus presence is associated with high blood pressure or high sugar level or both or not associated???

Eligibility criteria: Inclusion Criteria

* Egyptian citizens from 18 years to 80 years.

Exclusion Criteria:

* Patients younger than 18 years or older than 80 years

Primary outcomes:
measure: HCV diagnosis
timeFrame: 20 minutes
measure: Measurement of blood sugar level in mg/dl
timeFrame: 1 minute
measure: Measurement of systolic blood pressure in mmHg
timeFrame: 1 minute
Secondary outcomes:
Other outcomes:
Locations:
city: Asyut
country: Egypt
facility: Egyptian Ministry of Health
Study officials:
References:
Clinical trial NCT05809479: NICE - Nutritional Impact on Immunological Maturation During Childhood in Relation to the Environment
Official title: NICE - Nutritional Impact on Immunological Maturation During Childhood in Relation to the Environment
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Chronic Diseases in Children
Lead sponsor: Umeå University
Sponsor class: OTHER
Collaborators: name: Göteborg University
name: Chalmers University of Technology
name: Karolinska Institutet
name: Region Norrbotten
name: The Swedish Research Council
name: Forte
name: The Swedish Research Council for Environment, Agricultural Sciences and Spatial Planning (FORMAS)
First posted: 2023-04-12
Enrollment: 1950
Sex: ALL
Maximum age (years): 6
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 650 families (mother/father/child).

Brief summary: Role of the exposome on allergy, caries, and neurophysiological development in childhood.

Detailed description: Role of the exposome and epigenetics on allergy, caries, and neurophysiological development in childhood as studied in a birth cohort of 650 trioses. The exposome includes repeated measures of nutrition, micronutritients, microbiota, toxic agents and the clinical outcomes, diagnoses of allergy, caries and neurophysiological functions/dysfunctions.

Eligibility criteria: Inclusion Criteria:

* Born at Sunderby hospital, Region Norrbotten, during time period 2015-2018

Exclusion Criteria:

* Parents not able to speak or write Swedish

Primary outcomes:
measure: Number of participants with excema
timeFrame: Outcome at one year
measure: Number of participants with food allergy
timeFrame: Outcome at one year
measure: Number of participants with frhino-conjuctivitis
timeFrame: Outcome at one year
measure: Number of participants with asthma
timeFrame: Outcome at one year
measure: Number of participants with excema
timeFrame: Outcome at four years
measure: Number of participants with food allergy
timeFrame: Outcome at four years
measure: Number of participants with rhino-conjunctivitis
timeFrame: Outcome at four years
measure: Number of participants with asthma
timeFrame: Outcome at four years
measure: Number of participants with excema
timeFrame: Outcome at six years
measure: Number of participants with food allergy
timeFrame: Outcome at six years
measure: Number of participants with rhino-conjunctivitis
timeFrame: Outcome at six years
measure: Number of participants with asthma
timeFrame: Outcome at six years
measure: Numbers of caries lesions (DeMFS = decayed, enamel included, missed, filled, tooth surfaces, in each child
timeFrame: Outcome at four years
measure: Child cognition as measured by Wechsler Preschool and Primary Scale of Intelligence
timeFrame: Outcome at four years
Secondary outcomes:
Other outcomes:
Locations:
city: Luleå
country: Sweden
facility: Sunderby Hospital
state: Norrbotten County
Study officials:
affiliation: Umeå University
name: Anna Sandin, Ass Prof
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04584879: Transdiagnostic Treatment Personalization
Official title: Transdiagnostic Treatment Personalization: Prioritizing Therapy Components to Capitalize on Strengths or Compensate for Weaknesses
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Anxiety Disorders
Depressive Disorder
Post Traumatic Stress Disorder
Obsessive-Compulsive Disorder
Keywords: Unified Protocol
Cognitive Behavioral Therapy
Personalization
Lead sponsor: University of Kentucky
Sponsor class: OTHER
First posted: 2020-10-14
Enrollment: 72
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The primary purpose of this study is to explore whether the efficiency of treatment for anxiety and depressive disorders can be increased using two discrete strategies: personalized skill ordering and 2) treatment discontinuation based on proximal indicators of improvements. The present study will specifically use treatment components drawn from an evidence-based psychological intervention, the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP). This intervention has strong empirical support for patients presenting with anxiety, depressive, and related disorders and contains therapeutic skills that are common in psychological interventions (e.g., psychoeducation, mindfulness training, cognitive restructuring, countering emotional avoidance, increasing interoceptive tolerance). This study will determine if prioritizing the order of treatment modules to capitalize on patient strengths or compensate for weakensses increases treatmen efficacy. Additionally, it will also identify under what conditions briefer treatment modules may be appropriate.


Eligibility criteria: Inclusion Criteria:

* diagnosis of at least one emotional disorder
* fluent in English
* medication stability

Exclusion Criteria:

* concurrent therapy
* psychological condition that would be better addressed by alternative treatments
* have received more than 5 sessions of cognitive behavioral therapy in the past 5 years

Primary outcomes:
measure: Change in Clinical Severity
timeFrame: 12 weeks (baseline, week 6 and week 12)
measure: Change in Anxiety Symptoms
timeFrame: 12 weeks (baseline, week 1, week, 2, week, 3.....week 12)
measure: Change in Depressive Symptoms
timeFrame: 12 weeks (baseline, week 1, week, 2, week, 3.....week 12)
measure: Change in Aversive Reactions to Emotions
timeFrame: 12 weeks (baseline, week 1, week, 2, week, 3.....week 12)
Secondary outcomes:
Other outcomes:
Locations:
city: Lexington
country: United States
facility: University of Kentucky
state: Kentucky
Study officials:
affiliation: University of Kentucky
name: Shannon Sauer-Zavala
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00517179: Effect of Vardenafil on Blood Pressure in Patients With Erectile Dysfunction Who Received Concomitant Doxazosin GITS
Official title: Effect of Vardenafil on Blood Pressure in Patients With Erectile Dysfunction Who Received Concomitant Doxazosin GITS for the Treatment of Benign Prostatic Hyperplasia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Prostatic Hyperplasia
Impotence
Keywords: Benign Prostatic Hyperplasia (BPH)
Erectile Dysfunction (ED)
Lead sponsor: Hospital Authority, Hong Kong
Sponsor class: OTHER_GOV
First posted: 2007-08-16
Enrollment: 40
Sex: MALE
Minimum age (years): 50
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to investigate the interaction between doxazosin GITS and vardenafil on blood pressure (Both systolic and diastolic blood pressure) in patients with both ED and BPH.


Eligibility criteria: Inclusion Criteria:

* Age between 50 to 80 years old
* Clinically diagnosed to have lower urinary tract symptoms secondary to BPH:

  1. Suffered from lower urinary tract symptoms with International Prostate Symptom Score (IPSS) \>=8
  2. Detectable prostatic enlargement determined by Digital Rectum Examination (DRE)
  3. Urinary flow between 5 to 15ml/second in a total void volume \>=150mL
* Currently on regular doxazosin GITS once-daily for at least 4 weeks without clinically significant side effects
* Complaints of erectile dysfunction with Erectile Function domain (EF) of the International Index of Erectile Function (IIEF) score \<= 21

Exclusion Criteria:

* Congestive heart failure, unstable angina, arrhythmia, myocardial infraction
* Hypertension or on any antihypertensive agents
* Take nitrate and medication contradicted to vardenafil
* Uncontrolled or poorly controlled diabetes mellitus
* Intolerance or contra-indicated for the use of vardenafil
* Hepatic disorder

Primary outcomes:
measure: Mean maximal change of the standing systolic blood pressure (SBP) from half hour prior to till six hour after administration of the drug (baseline) with vardenafil administration versus placebo
timeFrame: From half hour prior to till six hour after administration of the drug (baseline)
Secondary outcomes:
measure: Mean maximal post-baseline change of the standing and supine diastolic blood pressure (DBP)
timeFrame: From half hour prior to till six hour after administration of the drug (baseline)
measure: Mean maximal post-baseline change supine SBP, and (3) the pattern of changes of the SBP and DBP from half hour prior to till six hours after administration of the drug
timeFrame: From half hour prior to till six hour after administration of the drug (baseline)
Other outcomes:
Locations:
city: Hong Kong
country: China
facility: Prince of Wales Hospital
Study officials:
affiliation: Department of Surgery, Division of Urology, The Chinese University of Hong Kong
name: Chi Fai Ng, Dr
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01402479: An Open-labeled Trial of Ramipril in Patients With Migraine
Official title: An Open-labeled Trial of Ramipril in Patients With Migraine
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Migraine With Hypertension
Keywords: migraine,
ramipril,
hypertension
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2011-07-26
Enrollment: 50
Sex: ALL
Minimum age (years): 20
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Physiology of migraine involving renin-angiotensin systems (RAS) has been implicated. Ramipril is a broadly-used angiotensin-converting enzyme inhibitor. The investigators attempt to test the efficacy of ramipril on the prophylaxis of migraine attacks.


Eligibility criteria: Inclusion Criteria:

* Patients with chronic migraine are included in this study. Migraineurs should be aged 20 to 70 years old with the ability to read and understand the self-report scales, including the headache diary, used in this study.

Exclusion Criteria:

1. Medication overuse headache are excluded in this study.
2. Treatment with other ACEI or medication that may affect ARS
3. Treatment with migraine prophylactic medications or anti-hypertensive agents including β adrenergic receptor or calcium channel blockers
4. Past history of hepatic or renal dysfunction; an abnormal electrocardiography; a psychiatric disorder; a history of substance abuse; pregnancy or lactation; use of anti-psychotics, antidepressants, or anti-anxiety drugs.

Primary outcomes:
measure: headache frequency
timeFrame: 12 week
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
Study officials:
References:
Clinical trial NCT05600179: OCTA in Epivascular Glia After Dex Implant
Official title: Evaluation of Changes in Epivascular Glia Before and After Intravitreal Dexamethasone Implant : an OCT Pilot Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Diabetic Retinopathy
Lead sponsor: Federico II University
Sponsor class: OTHER
First posted: 2022-10-31
Enrollment: 38
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The participans were older than 18 years with diagnosis of inflammatory diabetic macular edema glaucoma..

Brief summary: The aim of this prospective study was for the first time, to analyze specific morphologic features in diabetic eyes with macular oedema, such as changes of the foveal avascular zone and the presence of epivascular glia, and see how they would change after dexamethasone intravitreal implant


Eligibility criteria: Inclusion Criteria:

* diabetic retinopathy complicated by macular edema

Exclusion Criteria:

* congenital eye disorders,
* previous diagnosis of other ocular diseases
* history of vitreous hemorrhage

Primary outcomes:
measure: Changes in epivascular glia after Dexamethasone implant in patients with diabetic retinopathy and inflammatory macular edema
timeFrame: up to 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Naples
country: Italy
facility: University of Naples "Federico II"
Study officials:
References:
Clinical trial NCT03479879: Estradiol Pretreatment With Misoprostol in Second Trimester Miscarriage
Official title: Estradiol Pretreatment With Misoprostol in Second Trimester Miscarriage: A Prospective, Double-blind, Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Miscarriage
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2018-03-27
Enrollment: 200
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To compare the effectiveness of estradiol pretreatment with misoprostol and vaginal misoprostol alone in induction of second trimestr miscarriage.


Eligibility criteria: Inclusion Criteria:

* Maternal age more than 18 years old (age of legal consent).
* Gestational age between 12-26 weeks.
* Hb level \> 10 g/dL.
* BMI between 25 kg/m2 and 35 kg/m2.
* Missed abortion.
* Living fetus with multiple congenital malformations incompatible with life.
* PPROMS with drained liquor and parents are consenting for termination of pregnancy.

Exclusion Criteria:

* Maternal age less than 18 years old.
* Gestational age less than 12 weeks or more than 26 weeks.
* Hb level \< 10 g/dL.
* Scared uterus (previous myomectomy - cesarean section - hysterectomy and ruptured uterus).
* Polyhydramnios.
* Anencephaly.
* Fibroid uterus.
* BMI less than 25 kg/m2 and more than 35 kg/m2.
* Coagulopathy.
* Previous attempts for induction of abortion in the current pregnancy.
* Allergy to misoprostol or estradiol.
* Placenta previa.
* Medical disorder that contraindicate induction of abortion (e.g. heart failure).

Primary outcomes:
measure: Duration of induction of abortion
timeFrame: 24 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Ain Shams University Maternity Hospital
Study officials:
References: